Business Wire

Large-Scale Study Provides First-Ever Insights into the Genetic Causes of Bedwetting

Jaa

New evidence from the world’s first genome-wide association study (GWAS) identifies genes and genetic variants associated with bedwetting and may lead to earlier identification of children predisposed to bedwetting and improved earlier treatment options.The results are being presented by the International Children’s Continence Society (ICCS) and the European Society for Paediatric Urology (ESPU) on World Bedwetting Day on 29 May 2018.

“We have known for over a century, there has been strong evidence suggesting a genetic background for bedwetting.2 The risk of bedwetting is 5-7 times higher among children with a parent who suffered from bedwetting as a child, and approximately 11 times higher if both parents were bedwetters”,1 said Dr. Søren Rittig, Professor at the Department of Child and Youth, Nephro-urologic Team, Aarhus University Hospital who together with associate professor Jane Hvarregaard Christensen, Department of Biomedicine, Aarhus University is responsible for this new study.

Bedwetting is a common medical condition that has a serious impact on a child’s self-esteem, emotional well-being and day time functioning, including school and social performance3,4,5; and improvements in their working memory and other daily activities have been seen after treatment.6

The GWAS used the iPSYCH2012 nationwide population-based sample of around 80,000 Danish individuals collected to study among others ADHD and autism. Genome-wide association studies work by scanning markers across the entire genome of large numbers of people in order to find genetic variants associated with a particular disease.

Associate professor Jane Hvarregaard Christensen said, “By comparing the frequency of millions of genetic variants in thousands of DNA samples from bedwetting children we have been able to demonstrate specific genetic variants that each contribute to increase the risk of bedwetting. The genes implicated by this are known to function in deep brain areas responsible for regulation of day-night rhythms, urine production and sleep. This supports that bedwetting is linked to physiological mechanisms rather than being caused by psychological problems.” This is an important first step to provide new insights into the biological processes leading to bedwetting.

There are at least two main reasons why children are bedwetting – a reduced bladder capacity and/or an increased urine production during night-time (polyuria). By analyzing millions of genetic variants in bedwetting children, researchers were able to point to specific genes and thereby suggest specific biological causes of bedwetting.

Dr. Søren Rittig said, “We believe further research using the genes and genetic variants we have detected could help us identify bedwetting children earlier, determine which children would benefit from medication and tailor treatment to alleviate their condition.”

About Bedwetting

Bedwetting, also known as nocturnal enuresis, is an uncontrollable leakage of urine while asleep.7 In most cases it is caused by over-production of urine at night or reduced capacity of the bladder.4 An inability to wake up can be another cause.4 Bedwetting does not seem to have a psychological cause.4 Bedwetting is a common childhood medical condition, with approximately 5–10% of 7-year-olds regularly wetting their beds and the problem may persist into teenage and adulthood.8

About World Bedwetting Day

World Bedwetting Day was initiated to raise awareness among the public and healthcare professionals that bedwetting is a common medical condition that can and should be treated.

World Bedwetting Day 2018 will take place on 29 May and occurs on the last Tuesday of May each year. The theme is: ‘Time to Take Action’, in recognition that much more can be done to diagnose and treat those children who suffer from bedwetting.

For more information please visit www.worldbedwettingday.com.

About the World Bedwetting Day Steering Committee

The World Bedwetting Day Steering Committee brings together experts from across the globe to support this initiative and consists of the International Children’s Continence Society (ICCS), the European Society of Paediatric Urology (ESPU), the Asia Pacific Association of Paediatric Urology (APAPU), the International Paediatric Nephrology Association (IPNA), the European Society of Paediatric Nephrology (ESPN), the Sociedad Iberoamericana de Urologia Paediatrica (SIUP), and the North American Paediatric Urology Societies. The initiative is supported by Ferring Pharmaceuticals.

References

1 Jarvelin, M. R., Vikevainen-Tervonen, L., Moilanen, I. & Huttunen, N. P. Enuresis in seven-year-old children. Acta paediatrica Scandinavica 77, 148-153 (1988).
2 von Gontard, A., Schaumburg, H., Hollmann, E., Eiberg, H. & Rittig, S. The genetics of enuresis: a review. The Journal of urology 166, 2438-2443 (2001).
3 Iannelli V. Bedwetting. Available at https://www.verywell.com/bedwetting-bedwetting-statistics-2633257. Last accessed January 2017.
4 Vande Walle J et al, Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012;171:971-98
5 Joinson C et al. A United Kingdom population-based study of intellectual capacities in children with and without soiling, daytime wetting, and bed-wetting Pediatrics. 2007;120(2):e308-16
6 Van Herzeele C, Dhondt K, Roels S P et al. Desmopressin (melt) therapy in children with monosymptomatic nocturnal enuresis and nocturnal polyuria results in improved neuropsychological functioning and sleep. Pediatr Nephrol. 2016; DOI 10.1007/s00467-016-23351-3
7 Austin P et al. The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Update Report from the Standardization Committee of the International Children’s Continence Society, The Journal of Urology. 2014;191:1863-1865
8 Nevéus T. Nocturnal enuresis—theoretic background and practical guidelines. Pediatr Nephrol. 2011; 26:1207–1214

Contact information

Burson-Marsteller, on behalf of World Bedwetting Day Steering Committee
Jack Dixey, +44 (0)207 300 6221
Jack.Dixey@bm.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Alibaba’s Robust Ecosystem Supercharges 2018 11.11 Global Shopping Festival19.10.2018 13:15Tiedote

Alibaba Group Holding Limited (NYSE:BABA) today officially kicked off the 2018 11.11 Global Shopping Festival in China’s capital, promising this year’s mega-event will be the largest-ever in terms of scale and reach. Businesses within the Alibaba ecosystem will jointly offer hundreds of millions of consumers an enriching experience that supports their pursuit of high-quality products, entertainment and fast, reliable services. The Festival will also demonstrate the enthusiasm of consumers and brands embracing Alibaba’s New Retail strategy – the convergence of online and offline retail through technology. “This year marks the 10th anniversary of 11.11. On the back of China’s explosive digital transformation, the Festival’s astounding growth over the past decade has powered the steady growth of quality consumption sought by Chinese shoppers. The evolution also showcases the development of the Alibaba ecosystem over time expanding well beyond e-commerce,” said Alibaba Group CEO Daniel Zha

Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC19.10.2018 13:08Tiedote

Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). The results showed that the sequential strategy was effective in delaying subsequent chemotherapy treatment and were published today in the journal Future Oncology. According to the study, the median time on treatment for sequential afatinib and osimertinib was 27.6 months. In this broad, real-world population, the clinical benefit was consistent across all patient subgroups, with particularly encouraging results seen in those with exon 19 deletion (Del19)-positive disease (median time on treatment 30.3 months) and Asian patients (median time on treatment 4

Clovis Oncology Presents Initial Results from the Ongoing Rubraca® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer (mCRPC) at ESMO 2018 Congress19.10.2018 13:01Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology). The data show a 44% confirmed objective response rate (ORR) by investigator assessment in 25 RECIST* /PCWG3** response-evaluable patients with a BRCA1/2 alteration. The median duration of response in these patients has not yet been reached. In addition, a 51% confirmed prostate specific antigen (PSA) response rate was observed in 45 PSA response-evaluable patients with a BRCA1/2 alteration. The TRITON2 results were the basis for Breakthrough Therapy designation for Rubraca as a monotherapy treatment of adult patients with BRCA1/2 mutated mCRPC who have received at least one prior androgen receptor (AR)-directed therapy and taxane-based chemotherapy, which was granted on October 2, 2018 by the U.S. Food and Drug Administration (FDA). These data will be highlighted in a poster authored by Dr. Wassim

EMVCo Publishes Draft EMV® Secure Remote Commerce Specification v0.9 for Public Comment19.10.2018 12:00Tiedote

EMVCo has today published a draft of its EMV® Secure Remote Commerce (SRC) Specification, which is available for download from the EMVCo website and open for a public comment period of 45 days, until Monday 3 December. The global technical body has made the decision to release a draft specification - EMV SRC Specification v0.9 – before finalising the specification to allow as many payment industry participants as possible, including merchants, card issuers and payment networks, the opportunity to review and contribute to v1.0 which will be published in 2019. The draft EMV SRC Specification provides a foundation that will enable the processing of e-commerce transactions in a consistent, streamlined fashion across a variety of digital channels and devices, including smartphones, tablets, PCs and other connected devices. When finalised, it is expected that v1.0 of the EMV SRC Specification will: Define interfaces to allow for secure exchanges of payment data across participants in the dig

Reorg Acquires Majority Stake in Debt Explained19.10.2018 11:00Tiedote

Reorg, a leading financial media and technology company, today announced it has acquired a controlling stake in London-based Debt Explained Limited, the leading provider of data and analysis on the European high-yield and leverage loan markets. Founded in 2009, Debt Explained creates and curates data and analysis on bond and loan deals through its proprietary data bases and unique scoring and bench-marking products. These allow for detailed trend analysis in the European high yield and leverage loan markets. The combination of Reorg and Debt Explained will make these tools available on a global basis, driving a new and unique subscriber experience in Europe, the United States and beyond. “Reorg’s partnership with Debt Explained will create the industry-leading product in the global non-investment grade credit markets,” said Kent Collier, founder and chief executive officer of Reorg. “This fits in perfectly with our strategic vision, and we look forward to building our business together

MapleStory 2 Hits 1 Million Account Downloads18.10.2018 23:43Tiedote

MapleStory 2, the newest leading free to play MMORPG in the illustrious and vibrant setting of Maple World, has officially hit 1 million account downloads, only a week after its launch. MapleStory 2 is available for download globally on Nexon Launcher and Steam. Since its official launch, MapleStory 2 has become one of the biggest MMORPGs on Steam and a beloved game for 1 million players due to its unlimited customization, quests, and its fun community. Due to its rapid growth, the game continues to increase its servers, especially the Oceania server, where player population continues to exceed expectations. To celebrate the occasion, MapleStory 2 will hold various events to commemorate the achievement and thank its players. MapleStory 2 1 Million Player Celebration Events: Double Bonus Item Drop Event: Starting Friday, Oct. 19 and going until Friday, Oct. 26, players will be able to earn double bonus items from normal adventure dungeons. Special Weekend Login Event: Beginning Saturday

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme